Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.17537 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spesolimab in refractory paediatric acrodermatitis continua of Hallopeau, a case series.
J Eur Acad Dermatol Venereol
December 2024
Dermatology Hospital of Southern Medical University, Guangzhou, China.
Refractory acrodermatitis continua of Hallopeau successfully treated by baricitinib: A case report.
J Dermatol
November 2024
Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Rapid Improvement in Refractory Acrodermatitis Continua of Hallopeau With Spesolimab Injection.
Clin Exp Dermatol
October 2024
Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, 210042, China.
Gianotti-Crosti syndrome mimicking scabies.
Infection
October 2024
Department of Dermatology, Hospital Universitario y Politécnico La Fe, 106 Fernando Abril Martorell Avenue, 46026, Valencia, Spain.
This case report highlights a case of a 65-year-old woman who presented to our clinic with suspicion of refractory scabies. She had undergone multiple treatments without improvement. However, the clinical condition was not scabies but rather Gianotti-Crosti Syndrome (GCS), leading to rapid clinical improvement and avoiding the need for further unnecessary tests and treatments.
View Article and Find Full Text PDFSuccessful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report.
Front Immunol
March 2024
Department of Dermatovenerology, West China Hospital, Sichuan University, Chengdu, China.
Article Synopsis
- - Generalized pustular psoriasis (GPP) is a rare, painful skin condition marked by sterile pustules and lacks standardized treatment options; biologics have been used with mixed results.
- - Acrodermatitis continua of Hallopeau (ACH) is a severe variant of pustular psoriasis that is difficult to treat, and it shares a common pathogenic mechanism with GPP involving the IL-36 signaling axis.
- - A case study of an Asian patient with a long history of both GPP and ACH showed significant improvement in skin and nail lesions after receiving spesolimab, suggesting its potential effectiveness for treating ACH in patients with GPP.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!